Diligence memo · auto-generated · as of July 2, 2026
Branch Therapeutics, Inc.
Branch Therapeutics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Branch Therapeutics, Inc. operates in Pharmaceuticals, based in HOUSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Branch Therapeutics, Inc. has raised $4.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $4.0M on 2025-04-30.
Most recent recorded round closed around 2025-04-30.
Valuation (modeled)modeled
Provath models Branch Therapeutics, Inc. at approximately $12M (range $3.0M–$26M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.02× the median modeled value of Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 14 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 38% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 21% of those peers.
Closest niche peers: Kairos Pharma, LTD., ResBiotic Nutrition, Inc., Califia Pharma, Inc., BTB Therapeutics, Inc., Avana Health, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.